Growth medium effect on the antifungal activity of LY 303366

被引:21
作者
Klepser, ME
Ernst, EJ
Ernst, ME
Pfaller, MA
机构
[1] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA
[2] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA
[3] Univ Iowa, Coll Med, Iowa City, IA 52242 USA
关键词
D O I
10.1016/S0732-8893(97)00144-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The impact of growth medium selection on antifungal susceptibility testing has been well documented. Previously we described the antifungal characteristics of LY 303366 via time-kill curve methods using RPMI 1640 buffered with 0.165 M morpholinepropane-sulfonic acid as growth medium. The purpose of the current study was to compare the previously reported kill curve results with results obtained using antibiotic medium number three (AM #3) as growth medium. Antifungal activity was assessed via susceptibility testing and time-kill studies in both media. Two isolates each of Candida albicans, C. glabrata, and C. tropicalis were studied. MICs for fire six isolates were found to be 10 to 100 times lower in AM #3. Time-kill studies were conducted with multiples of the MIC ranging from 0.125 x MIC to 16 x MIC. LY 303366 exhibited fungicidal (greater than or equal to 3 log(10) reduction in CFU) activity against all isolates in AM #3; however, fungicidal activity was noted only for three of the six isolates when tested in RPMI. Furthermore, the rate of fungicidal activity was more rapid when AM #3 was utilized. Not only were the rate and extent of activity influenced by choice of media, but the relationships between LY 303366 concentrations and activity were also found to be media dependent. The findings from this study serve to highlight further the importance of media selection for in vitro evaluation of antifungal activity. In vivo studies need to be conducted with LY 303366 to determine which media provides the best correlation between in vitro and in vivo findings. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:227 / 231
页数:5
相关论文
共 9 条
  • [1] RIGHT-SIDED STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN INTRAVENOUS DRUG-ABUSERS - 2-WEEK COMBINATION THERAPY
    CHAMBERS, HF
    MILLER, RT
    NEWMAN, MD
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 109 (08) : 619 - 624
  • [2] ERNST ME, 1996, DIAGN MICROBIOL INFE, V26, P126
  • [3] FRIESEN M, 1996, 36 INT C ANT AG CHEM, P108
  • [4] Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
    Klepser, ME
    Wolfe, EJ
    Jones, RN
    Nightingale, CH
    Pfaller, MA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1392 - 1395
  • [5] KLEPSER ME, 1996, 34 ANN M INF DIS SOC, P50
  • [6] *NAT COMM CLIN LAB, 1997, REF METH BROTH DIL A
  • [7] METHOD FOR RELIABLE DETERMINATION OF MINIMAL LETHAL ANTIBIOTIC CONCENTRATIONS
    PEARSON, RD
    STEIGBIGEL, RT
    DAVIS, HT
    CHAPMAN, SW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (05) : 699 - 708
  • [8] COLLABORATIVE INVESTIGATION OF VARIABLES IN SUSCEPTIBILITY TESTING OF YEASTS
    PFALLER, MA
    RINALDI, MG
    GALGIANI, JN
    BARTLETT, MS
    BODY, BA
    ESPINELINGROFF, A
    FROMTLING, RA
    HALL, GS
    HUGHES, CE
    ODDS, FC
    SUGAR, AM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) : 1648 - 1654
  • [9] VANCOMYCIN FOR STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN INTRAVENOUS-DRUG-USERS
    SMALL, PM
    CHAMBERS, HF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) : 1227 - 1231